- GlobeNewswire•19 hours agoCatalyst Pharmaceuticals Provides Update on its Clinical Trial for Patients with Congenital Myasthenic Syndromes
Allowing adult CMS patients to participate Number of patients increased to approximately 20 Additional site added CORAL GABLES, Fla., Dec. 08, 2016-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical ...
- Capital Cube•8 days agoCatalyst Pharmaceuticals, Inc. :CPRX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
Categories: Yahoo Finance Get free summary analysis Catalyst Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2016. Analysis Summary numbers: Revenues of USD 0 million, Net Earnings of USD -3.95 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless. CPRX-US‘s earnings ... Read more (Read more...)
- GlobeNewswire•18 days ago
CORAL GABLES, Fla., Nov. 21, 2016-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, ...
CPRX : Summary for Catalyst Pharmaceuticals, Inc. - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (CPRX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Day's Range||1.10 - 1.18|
|52 Week Range||0.51 - 3.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.83|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|